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AFFYMETRIX'
A review of the agenda for this conference is a reminder of the
tremendous challenge before all of us who are trying to build an
ethical, legal, social, and economic bridge as we cross into this
next era of genomics and proteomics, and all the other "...omics"
buzzwords that seem to be coming out of biotechnology. I notice
there is a question mark after "Revolution" in the program title. I
have to object to that question mark, because I think there is no
question; there is a revolution. But I also appreciate the fact that
there is not an exclamation mark up there, because there is an
awful lot of hype that runs through all of this. I think it is good to,
on the one hand, think about all of these tough questions we are
going to confront, but on the other hand, we should be grounded in
reality and think about where we are today. We should
contemplate how we need to literally put one legal, ethical, and
social foot in front of the other to move forward responsibly.
Publication of the human genome, and the realization that we
are all 99.9 percent the same, that we essentially share those three
billion base pairs,2 is a significant rite of passage. And yet, so
much of this is about that one-tenth of one percent that we are all
trying to figure out-the small percentage of DNA variation that
differentiates us and makes most of us susceptible to some
diseases.
Affymetrix is in the business of making a tool that, we think, is
one of the fundamental points in understanding how to catalogue,
how to decipher, how to interpret, and how to use this information.
Our existing technology includes fitting the human genome on a
chip the size of a postage stamp.
Copyright 2005, by LOuIsIANA LAW REVIEW.
J.D., V.P. Government Affairs, Affymetrix. This work is based upon a
live presentation made on February 5, 2004, and does not necessarily reflect
events and changes thereafter.
1. Information about Affymetrix, a bioinformatics company based in
California, is available at http://www.affymetrix.com.
2. For information about the Human Genome Project and related advances,
visit the site of the National Human Genome Research Institute,
http://www.genome.gov.
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There are two great dimensions to the genome, and you can
think of them as micro and macroeconomic if you will. On the
bottom is DNA analysis, and that is sort of macroeconomic-for
example, looking across an entire population to understand the
differences among people within that population. And this gets
back to the point that Michael was making about biobanks. A
dimension above that, we ask the microeconomic question. We
look out and we ask Michael, "What, specifically, is happening in
your genome that would tell us if you have a certain condition,
how you'll respond to certain medication, what your prognosis
might be?" And so on and so forth. How do we take that
understanding of you and reduce it to a molecular level? The word
"reduce" is a misnomer because "reduce" sounds like there is less
of something. But, in fact, by taking things down to a molecular
level, the amount of information we are getting is so much more
powerful that we are actually exponentially expanding our
understanding of the human condition.
Affymetrix's founder's great idea was to take the principles of
combinatorial chemistry and marry them to the principles of
semiconductor manufacturing in Silicon Valley. 3 And this really
predates, by almost a decade, the publication of the genome
because, even as early as 1991 when our founder's paper was
published in Science, people were starting to understand that
completion of a map of the genome would bring an abundance of
information. It would bring all of those As and Cs and Gs and Ts,
which could stretch between Portland and Chicago fifty times over,
or between here and the moon, or fill up 9,000 newspapers. We
use a bunch of these wonderful illustrations to capture how much
information is involved.
Affymetrix was founded with a focus on moving from fusing
transistors on a chip to fusing DNA and RNA on a chip.
Increasingly, foremost for developing pharmaceuticals with
genomics, including drug discovery, is the notion of looking across
a population to understand genetic variance and how that might
impact a condition. Secondly, drug validity must be understood on
a genetic level-meaning understanding what will and will not
work based on genetic insight for what drug targets would be valid,
3. Affymetrix's "GeneChip" technology was invented in the late 1980s by
a team of scientists headed by the company's founder, Stephen P.A. Fodor,
Ph.D. See Affymetrix, Corporate History, http://www.affymetrix.com/corporate
/history/index.affx.
4. Stephen P.A. Fodor et al., Light-Directed, Spatially Addressable
Parallel Chemical Synthesis, 251 Science 767-73 (1991).
5. See id
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rather than based on the outcome of a winding process of clinical
trials involving some 5,000 people. The goal is to be smarter,
more selective.
Our whole paradigm of what constitutes success, or lack
thereof, in drugs is changing. In the old days, we said, "Well, this
drug works for sixty-five to seventy percent of the people. That
means it is a pretty good drug." If you are in the thirty percent that
it did not work for, you are not going to be very happy about it.
But on the other hand, there may be a drug for which people said,
"Well, it is not all that effective, it only works thirty percent of the
time." If you are in that thirty percent, it is one hundred percent
effective. So, being able to stratify patients and the kinds of
pharmaceuticals we develop is a powerful application of the
technology.
And at last, clinical genomics. Today, most of this technology
is what the Food and Drug Administration ("FDA") calls "research
use only" (RUO) technology. But Affymetrix can move quickly,
as can others in the industry and the FDA, and there are the folks
in the clinic who would like to take this technology today and be
able to say with great definition from what types of conditions
people suffer.
I will tell you one quick, anecdotal story from a friend of mine,
Terry, who is the Medical Curator of the Smithsonian in
Washington, D.C. It is a story about Ulysses S. Grant, our only
president to have died from cancer.6 A series of biopsies were
taken, before and after he died, of the tumor that had lodged in his
throat.7 Those were kept at Walter Reed Army Hospital over the
many years that followed. In 1999, the Army decided to bring in a
group of pathologists to look at Ulysses S. Grant's tumor slides
and to try to discern what we would know today that we did not
know when Grant died in the 1880s.
8
The results were interesting, which Terry reported in "What's
in Grant's Tumor?," which I think is a great pun.9 They brought
all of these great pathologists in, and they all looked at a slide.1
0
And more than one hundred years later, what could they
definitively say that had not already been deduced in the 1800s?
6. See generally Josiah Bunting, III, Ulysses S. Grant (Arthur M.
Schlesinger, Jr. ed., Times Books 2004).
7. See generally T. Ready, Access to Presidential DNA Denied, 5 Nature
Med. 859 (1999); G. Terry Sharrer, What's in Grant's Tumor?.
8. Sharrer, supra note 7.
9. Id.
10. Id.
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The answer was nothing.'" They reached the same conclusion
because they had the same basic baseline of evidence to go on.
Now, that is not to suggest that the treatment of cancer has not
progressed; it certainly has. But the molecular understanding of
cancer is just beginning.
Now let me contrast that with some work that has been done
recently. Scientists started out looking at leukemia classifications
and leukemia cells. They began with this baseline of looking
under the microscope. But then they employed a chip-based
technology and they were able to decide which classification of
leukemia patients had, with ninety-five to ninety-nine percent
accuracy.' In fact, they updated this study in 2002 and found an
entirely new classification of leukemia that had not existed before,
just based on the gene expression profile.' 3
Now, why is that important? Medicine, as good doctors tell
you, is still a lot of art mixed with a lot of science. But the therapy
path, as with some of these treatments for leukemia, can be
dramatically different. They are excruciatingly difficult, they are
painful, and they are hard on families as well as patients. They are
certainly expensive for all of us as a society. And how would you
like to be the person who is halfway through the treatment protocol
for acute myelogenous leukemia ("AML"), only to hear, "Oh, gee,
you really had acute lymphoblastic leukemia ("ALL")?"
Clinically, we are talking about being able to give patients a
definitive diagnosis with understanding of the disease at an
unprecedented level of certainty, which is starting to happen now
and will arrive before we get way out there with the futuristic
world of personalized medicine.
The use of these technologies is quite far-ranging, for
everything that lives has a genome-plants, animals, viruses, and
bacteria. Consider the news starting around Christmas 2003 that
incidents of bovine spongiform encephalopathy ("BSE"), mad cow
disease, 14 were occurring again, and see the importance of
livestock and being able to tell the kind of feed that livestock
consumed. We have a chip that does that. Similarly, Affymetrix is
doing a lot of very interesting work with the Environmental
Protection Agency ("EPA") to think about how to come up with a
11. Id.
12. See generally Scott A. Armstrong et al., MLL Translocations Specify a
Distinct Gene Expression Profile that Distinguishes a Unique Leukemia, 30
Nature Genetics 41,41-47 (2002).
13. Seeid.
14. For information about BSE, visit the website of the U.S. Food and Drug
Administration, http://www.fda.gov/oc/opacom/hottopics/bse.html.
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whole new way of doing environmental impact assessments aside
from the thing we have been doing for fifty years, that is, taking
these poor mice down to the lab and seeing how many of them
make it and how many of them do not. There has got to be a
smarter way to do that, and we think we can find it.
What are the intellectual property issues and implications? I
approach this discussion, by necessity, from a parochial point of
view-as a private sector company that has evolved over the last
decade. And it may not go in the direction you think it is going to
go when I use the word "private sector," which is why it is a lot of
fun to talk about this. At Affymetrix, we started asking some very
fundamental questions about gene patents, and about their
justifiability based on, not just legal grounds, but also ethical,
economic, social, and commercial grounds. For instance, we use
many gene probes on our chips; the latest chip we just introduced
has 50,000 genes, which is actually more than the genome-it is,
in fact, the genome with redundancy built in. The feature size on
that chip is eleven microns, which means millions and millions of
bits of information, millions and millions of probes of information,
on that chip. Now, what if we had to pay a patent royalty for every
one of those probes that was on the chip? That is the most far-out
example I can give.
I want to start at that baseline and analyze the genome as a
resource, because I think it is probably our ultimate natural
resource. Part of what makes this conference so interesting is that
we are really charged with the stewardship of that resource, in
ways large and small. How are we, as a society, going to derive
the greatest benefit from this wonderful discovery?
All that I've told you about the genome, and all that we have
learned and all these wonderful slides that you are going to see
over the next few days is vastly outweighed by all we have yet to
learn. Francis Collins, who heads the National Human Genome
Research Institute, is always fond of sayin 5that this is "the end of
the beginning of where we are right now." Essentially, we have
just put down a baseline. We also know that there are about
35,000 genes in the human body, depending upon whose estimate
you want to believe. 16 What does that tell us from the start? Well,
we probably cannot say there is just one gene that gives you blue
eyes, one gene that gives you cancer, one gene that gives you heart
disease, and so on. There is a fair amount of single-gene disorder,
15. See Ania Lichtarowicz, The End of the Beginning, (2005),
http://news.bbc.co.uk/2/hi/sciencenature/1 100726.stm.
16. J. Michael McGinnis, Population Health and the Influence of Medical
and Scientific Advances, 66 La. L. Rev. (Special Issue) 9, 10 (2006).
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but they are not the norm. In fact, we at Affymetrix just did some
very interesting work with such disorders, which leads me to
believe we are going to end up with sub-biobanks in specialized
populations.
We just did a fascinating project with an Amish community in
Pennsylvania and, in one month's time, isolated the gene for a
birth defect called Swyer Syndrome, a single gene disorder.' But
most of the common complex diseases we are looking at are going
to be an interaction, we believe, of multiple genes doing multiple
things with one another, and interacting with the environments that
they are in. So there is an enormous amount of complexity out
there to understanding why certain genes on Mondays, Tuesdays,
and Fridays are doing this, and then on Thursdays and Saturdays
are doing that, and why they are interacting with one another in a
real social environment, if you will. Thankfully, this identification
of the added dimensions of complexity is accompanied by more
enabling technologies. More and more technology is coming
online, which is enabling scientists to address and interrogate the
whole genome, or significant chunks of the genome at one time,
rather than looking gene, by gene, by gene.
Now, what happens when the ability and the need to do this
research collides with property rights in that genome, created by an
intellectual property regime? Affymetrix has over 250 patents on
our technology and another 300 patents pending. So we are the
living embodiment of the importance of the patent system. This
intellectual property is very important, and it has been a singularly
important thing in building the commercial value of our company.
And that goes back to something Michael said which I think is not
even a debatable point: going forward will be an interaction of
government, academia, and the private sector, all commingling
with one another-sort of like the gene interactions I talked about.
Where are we going to set the property right bar along that genome
so that society gets the maximum benefit? How do we build
incentives into the system so that everyone can take advantage of
it, and yet recognize that inevitably there is going to be a request
for a return on value and investment? Eric Lander, of the
Whitehead Institute at the Massachusetts Institute of Technology,
17. Information about Affymetrix's research is available at http://
www.affymetrix.com. More recently, Affymetrix worked with an Amish
community in Lancaster, Pennsylvania to identify the gene responsible for a new
form of sudden infant death syndrome following the death of twenty-one Amish
babies from the disease. See Dr. Holmes Morton et al., A Modem Miracle in
the Most Traditional of Communities, Oct. 2004, http://www.affymetrix.com/
community/wayahead/modemmiracle.affx.
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is a pretty provocative guy. At a seminar in Washington, D.C. a
few years ago on these issues he questioned, "Aren't we awarding
limited time monopolies on mindless genetic innovation?" Of
course, what constitutes "mindless genetic innovation" is a
debatable point.
In addition to the basic genome I talked about, there is a whole
second order of discovery issues that are coming down the pike as
well-notions about what we do with proteomics, MRNA, and so
forth. And we will have a very difficult time setting legal
standards for those when, in my mind, we have not been able to
reach the right perspective for what we need to do with the
essential parts of the genome. We have been trying to break out of
the sort of traditional notion of gene patents, right or wrong, to
instead think about what our approach should be going forward.
How should we differentiate all these different pieces of genomic
information that are out there?
So far, our efforts have been largely to differentiate between
those items we think are cataloged in nature and those that
demonstrate some real functionality from which, in our view, there
would be true innovation in the art of discovery. By cataloging, I
mean sort of like the Sears catalog. There is quite a bit of
information out there that we think sort of falls into that category.
For example, the periodic table of elements. You could not walk
out of here tomorrow and patent iron. You could not walk out of
here and patent gold. We consider those to be part of nature. Mr.
Gray may have gotten a copyright on his drawings, but he could
not copyright part of the anatomy. The first person to ever see a
spleen could not have pulled that out and said, "Oops, this is mine.
No one else can use it without a license from me." There is a
culture of understanding that there are some things that are just
obvious, and obviousness is one of those terms that comes up a lot
in patent law. I am going to try very hard not to have us go down
into patent law minutia for this conversation but, rather, to stay
with some of the policy questions that I think are really
preeminent.
.As a company that has 250 patents, I cannot say that we do not
believe in intellectual property. We certainly do. And I think the
question is the point at which you say, "This entity has done
enough innovation to justify some degree of exclusivity taking
hold." We have discussed a commerce clause for the genome. An
interesting analogy is to think of the genome as a river. To
illustrate the point, consider the great Mississippi River flood of
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1927, which is wonderfully told in a book entitled Rising Tide.1 8
The good people of New Orleans decided that they did not like the
flow of the Mississippi so they got the Army Corps of Engineers to
build a very complicated and wonderful series of levees up and
down the river, which resulted in a disastrous flood and an
enormous social displacement of the whole mid-range of the
south.' 9 Anyway, if you said to people, "Well, if you go out to the
river, buy a piece of land on the side of the river, and develop that
and put a resort or some other facility there-something that adds
economic good-well, we will recognize and protect your rights in
that," that would be understandable. But if you were to allow
people to put up a toll booth every twenty feet along the
Mississippi today, how would commerce move up and down the
river and how would that benefit people?
Now, legally, are we going to be able to change the existing
scheme of intellectual property rights in the genome? Probably
not, but I do think there are some measures that could be taken to
mitigate this. One that I would like to talk about is the notion of
pooling in a resource. Incidentally, a few minutes ago, Michael
talked along similar lines and mentioned a potential role for the
World Health Organization ("WHO"). I think the Office for
Economic Development ("OECD") is another organization that
could be useful for working through issues and accomplishing
some collective good.
Affymetrix has advocated the establishment of a Biomarker
Pool. There was some precedent set earlier last year throuph
establishment of an agricultural pool by Rockefeller University.'
The notion was that there were a great many universities-and I
believe LSU was one of them-that had done great work in
developing agricultural products. They then had licensed that
work to companies like Monsanto, DuPont, and others, which took
these innovations and sort of put them on the shelf rather than
carrying them through to fruition. Consequently, there were a lot
of products that could, potentially, be very helpful in alleviating
hunger around the world that were not developed. And so the
Rockefeller Institute convened a meeting of all of the parties and
said, "Look, why don't we create a pooling arrangement where
we'll bring all of those patents back into a centralized database,
and then we'll allow other people who are doing non-profit
18. See generally John M. Barry, Rising Tide: The Great Mississippi Flood
of 1927 and How it Changed America (Simon & Schuster 1998).
19. See generally id.
20. See Richard C. Atkinson et al., Public Sector Collaboration for
Agricultural IP Management, 301 Science 174, 174-75 (2003).
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research, or who might even want to commercialize it in some
way, to take advantage of it. Let's get more people in on the action
and use the intellectual property that's there."
If you know anything about the computer industry, they
function with a very complicated pooling system as well, but it
does work. For example, DVD technology was stalled for a long
time because you had sixty companies holding different kinds of
patents. Finally, when the bulk of those companies came together
and put their patents in a pool, they moved the technology forward.
Affymetrix thinks that the concept of bringing some of the
patents, especially on gene sequencing, and especially for non-
profit, basic research is a good idea. The court of appeals for the
Federal Circuit has made it very clear that there is no research use
exemption under U.S. patent law.21 The options are to wait for
Congress to pass a research exemption, in which case I would
argue that we would all be very old before that happens.
Alternatively, we could do something that, hopefully, would bring
some of the interested players to the table and try to create the kind
of framework that at least allows basic research to go forward and
researchers to feel like they are not going to get a cease and desist
order from a patent-holder somewhere trying to block their work.
As I said at the outset, these are enormously complex issues, and I
embrace the remainder of this conference and the opportunity to
engage in further discussion of them.
21. See Integra Lifesciences I, Ltd., v. Merck KGaA, 331 F.3d 860 (Fed.
Cir. 2003), vacated, 125 S. Ct. 2372 (2005), remanded to 421 F.3d 1289 (Fed.
Cir. 2005). See generally Lawrence B. Ebert, In Favor of The Federal Circuit
Position in Merck v. Integra, 87 J. Pat. & Trademark Off. Soc'y 321 (2005).

